Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Global equities head toward big monthly gain, dollar falls
Post Content Post Views: 132
Crude inventory increased by 8.7M barrels for week ended Nov. 17 – EIA
Post Content Post Views: 140
Capital Power expands with $1.1B U.S. gas plants acquisition
Post Content Post Views: 159
Foxconn’s electric car unit falls in market debut amid tough industry outlook
Post Content Post Views: 135
Japan’s factory activity shrinks for 6th month on weak demand – PMI
Post Content Post Views: 123
Service Corporation International’s growth phase may be over
Post Content Post Views: 139